STML - ステムライン・セラピュ―ティクス (Stemline Therapeutics Inc.)

STMLのニュース

   3 Languishing Small-Caps That Should Perk Up in 2020  2019/12/30 15:30:00 TheStreet
Stemline Therapeutics, Entercom Communications and Ocular Therapeutix are three languishing small-cap stocks that offer reasons to think their shares will perform better in the New Year….MSFT
   Analysts Anticipate Stemline Therapeutics Inc (NASDAQ:STML) Will Post Quarterly Sales of $15.48 Million  2019/11/13 10:24:40 Modern Readers
Wall Street brokerages expect Stemline Therapeutics Inc (NASDAQ:STML) to post sales of $15.48 million for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Stemline Therapeutics’ earnings. The lowest sales estimate is $6.70 million and the highest is $21.33 million. The firm is expected to announce its next quarterly earnings results on […]
   Stemline Therapeutics downgraded to neutral from outperform at Wedbush  2019/05/13 11:15:12 MarketWatch
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.
   Stemline Therapeutics' (STML) CEO Ivan Bergstein on Q1 2019 Results - Earnings Call Transcript  2019/05/11 02:33:11 Seeking Alpha
Stemline Therapeutics, Inc (NASDAQ:STML) Q1 2019 Earnings Conference Call May 10, 2019 8:00 AM ET Company Participants Ken Hoberman – Chief Operating Officer Iv
   Stemline Therapeutics, Inc. (STML) Q1 2019 Earnings Call Transcript  2019/05/10 22:46:31 The Motley Fool
STML earnings call for the period ending March 31, 2019.
   Analysts Anticipate Stemline Therapeutics Inc (NASDAQ:STML) Will Post Quarterly Sales of $15.48 Million  2019/11/13 10:24:40 Modern Readers
Wall Street brokerages expect Stemline Therapeutics Inc (NASDAQ:STML) to post sales of $15.48 million for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Stemline Therapeutics’ earnings. The lowest sales estimate is $6.70 million and the highest is $21.33 million. The firm is expected to announce its next quarterly earnings results on […]
   Stemline Therapeutics downgraded to neutral from outperform at Wedbush  2019/05/13 11:15:12 MarketWatch
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.
   Stemline Therapeutics' (STML) CEO Ivan Bergstein on Q1 2019 Results - Earnings Call Transcript  2019/05/11 02:33:11 Seeking Alpha
Stemline Therapeutics, Inc (NASDAQ:STML) Q1 2019 Earnings Conference Call May 10, 2019 8:00 AM ET Company Participants Ken Hoberman – Chief Operating Officer Iv
   Stemline Therapeutics, Inc. (STML) Q1 2019 Earnings Call Transcript  2019/05/10 22:46:31 The Motley Fool
STML earnings call for the period ending March 31, 2019.
   Stemline Therapeutics (STML) Reports Q1 Loss, Tops Revenue Estimates  2019/05/10 11:45:03 Zacks Investment Research
Stemline Therapeutics (STML) delivered earnings and revenue surprises of -8.96% and 93.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
   Stemline Therapeutics' (STML) CEO Ivan Bergstein on Q1 2019 Results - Earnings Call Transcript  2019-05-10
Stemline Therapeutics, Inc (STML) Q1 2019 Earnings Conference Call May 10, 2019 8:00 AM ET Company Participants Ken Hoberman Chief Operating Officer Ivan Bergstein Chief Executive Officer Robert Francomano Senior Vice President Global Head of Commercial…

calendar